NVOS

Novo Integrated Sciences, Inc. Common Stock

NVOS

Market cap $2.84M

Delisted

NVOS was delisted on the 5th of November, 2024.

Back to rankings

About: Novo Integrated Sciences Inc is a medical care company. It provides specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, neurological functions, kinesiology, and others. It has two reportable segments: healthcare services which generates majority of the revenue, and product sales.

Employees: 230

Industrials Specialty Industrial Machinery

Financial journalist opinion

Novo Integrated Sciences Reports 2024 Fiscal Year Financial Results

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Reports 2024 Fiscal Year Financial Results.

Novo Integrated Sciences Reports 2024 Fiscal Year Financial Results

Novo Integrated Sciences Reports Fiscal Year 2024 Third Quarter Financial Results

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Reports Fiscal Year 2024 Third Quarter Financial Results.

Novo Integrated Sciences Reports Fiscal Year 2024 Third Quarter Financial Results

What's Going On With Novo Integrated Sciences Stock On Friday?

On Friday, Novo Integrated Sciences Inc NVOS announced it received notice of the commencement of disbursement for the complete monetization of a Standby Letter of Credit (SBLC).

What's Going On With Novo Integrated Sciences Stock On Friday?

Novo Integrated Sciences Receives Commencement of Disbursement Notice for SBLC Leasing and Monetizing Program

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences Receives Commencement of Disbursement Notice for SBLC Leasing and Monetizing Program.

Novo Integrated Sciences Receives Commencement of Disbursement Notice for SBLC Leasing and Monetizing Program

Novo Integrated Sciences: A Coil Spring Ready To Explode

Novo Integrated Sciences is a unique nano-cap company with the potential for massive growth through game-changing, non-dilutive financing. Novo is working towards closing 3 major funding transactions, including a $70M promissory note, $78M for the monetization of gemstones expected to deliver surplus cash, and a one-billion-dollar gold-backed bond. Success in securing funding will be a true inflection point for NVOS, dramatically changing the fortunes of the company for the better.

Novo Integrated Sciences: A Coil Spring Ready To Explode

Novo Integrated Sciences Receives Confirmation of Issuance of SBLC by HSBC for SBLC Leasing and Monetizing Program

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announced today that it has received confirmation of the issuance of a Standby Letter of Credit (“SBLC”) by HSBC for delivery by Swift MT760, as part of a program designed for monetizing SBLCs. As previously reported, the Company entered into an application for the monetizing program whereby the Company is projected to receive gross funding proceeds of approximately $78 million under the SB.

Novo Integrated Sciences Receives Confirmation of Issuance of SBLC by HSBC for SBLC Leasing and Monetizing Program

Novo Integrated Sciences' Board of Directors Approves Increase of Maximum Amount Under Stock Repurchase Program to $10 Million

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), today announced the Company's Board of Directors has approved an increase of up to $10 million maximum amount, from the previously announced up to $5 million maximum amount, for the repurchase of the Company's outstanding common stock from time to time in the open market at prevailing market prices or in privately negotiated transactions. The increased maximum amount available for purchase.

Novo Integrated Sciences' Board of Directors Approves Increase of Maximum Amount Under Stock Repurchase Program to $10 Million

Acenzia Selected to Participate in Protein Industries Canada Program to Develop Plant Based Protein Products

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announced today that its wholly owned Canadian subsidiary, Acenzia Inc. (“Acenzia”), has been selected by Protein Industries Canada to participate in a new project to bring new protein products with a superior nutritional amino acid profile to the global marketplace. The total project is expected to see approximately $5.4 million invested into the development, reformulation, and commerciali.

Acenzia Selected to Participate in Protein Industries Canada Program to Develop Plant Based Protein Products

Novo Integrated Sciences and RC Consulting Consortium Group Amend $70,000,000 Promissory Note

BELLEVUE, Wash.--(BUSINESS WIRE)---- $NVOS #AAPI--Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announced today the Company and RC Consulting Consortium Group LLC, in favor of SCP Tourbillion Monaco (“RC”), have amended the prepayment terms and conditions of the previously disclosed $70,000,000 promissory note, dated April 26, 2023 (the “RC Note”) to provide that, at any time after 12 months and no later than 60 months from the commencement of the term of the RC Note and prior to an e.

Novo Integrated Sciences and RC Consulting Consortium Group Amend $70,000,000 Promissory Note

KBRA Assigns AA- to Pennsylvania Turnpike Commission Turnpike Revenue Bonds, Series C of 2024; Affirms Related Ratings

NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns a long-term rating of AA- to the Pennsylvania Turnpike Commission Turnpike Revenue Bonds, Series C of 2024. KBRA additionally affirms: The long-term rating of AA- for the Commission's outstanding Turnpike Revenue Bonds The long-term rating of A+ for the Commission's outstanding Turnpike Subordinate Revenue Bonds The long-term rating of AA- for the Commission's outstanding Motor License Fund-Enhanced Turnpike Subordinate Special Revenue Bonds The Outlook f.

KBRA Assigns AA- to Pennsylvania Turnpike Commission Turnpike Revenue Bonds, Series C of 2024; Affirms Related Ratings

See News Rankings

Charts implemented using Lightweight Charts™